Has Fadi Kayali, MD received payments from drug or device companies?

Yes. Drug and device makers reported $5,871,081 in general payments to Fadi Kayali, MD across 2,210 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Fadi Kayali, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Fadi Kayali, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Fadi Kayali, MD

Medical Oncology · Sarasota, FLNPI 1003031212

Payments from drug & device makers

$5,871,081in general payments, 2019–2025

Across 2,210 payments — averaging $2656.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Genentech, Inc.$1.1M
Daiichi Sankyo Inc.$913K
Seagen Inc.$814K
Mirati Therapeutics, Inc.$656K
AstraZeneca$552K
Novartis$338K
plus $1.5M from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Genentech, Inc.	241	$1,104,396
Daiichi Sankyo Inc.	355	$913,158
Seagen Inc.	220	$813,670
Mirati Therapeutics, Inc.	56	$655,834
AstraZeneca(2 entities)	104	$551,639
Novartis	67	$338,492
Tesaro, Inc.	24	$314,438
E.r. Squibb & Sons, L.L.C.	75	$277,474
Astrazeneca UK Limited	26	$230,560
GSK	78	$202,381
Beigene, Ltd.	57	$111,803
Janssen Research & Development, LLC	19	$84,088
Verastem, Inc.	45	$52,415
Secura Bio, Inc.	31	$44,934
Pfizer	84	$44,191
AbbVie	77	$36,344
Incyte Corporation	87	$34,617
Jazz Pharmaceuticals Inc.	26	$21,052
Eli Lilly	7	$15,643
Myriad Genetic Laboratories, Inc.	3	$8,014
Avyxa Pharma, LLC	3	$2,533
Genentech USA, Inc.	25	$1,994
Bristol Myers Squibb	68	$1,445
Johnson & Johnson(3 entities)	92	$1,431
Merck	40	$927
AVEO Pharmaceuticals, Inc.	2	$918
Gilead(2 entities)	26	$625
Lilly USA, LLC	29	$537
Array Biopharma Inc	25	$507
Astellas Pharma US Inc	16	$423
Teva Pharmaceuticals USA, Inc.	2	$317
Eisai Inc.	13	$286
Coherus Oncology, Inc.	2	$264
Exelixis Inc.	9	$219
Amgen	11	$214
Beigene USA, Inc.	9	$210
Sanofi	10	$200
Rigel Pharmaceuticals, Inc.	5	$183
Pharmacyclics LLC, An Abbvie Company	8	$175
Takeda Pharmaceuticals U.S.A., Inc.	7	$162
EMD Serono, Inc.	9	$133
Boehringer Ingelheim	5	$124
Puma Biotechnology, Inc.	8	$123
Inari Medical, Inc.	1	$115
Regeneron Healthcare Solutions, Inc.	4	$107
Sumitomo Pharma America, Inc.	6	$106
Myovant Sciences Inc.	6	$94
Beone Medicines USA, Inc.	4	$93
Bayer	6	$91
Geron Corporation	3	$70
Alnylam Pharmaceuticals Inc.	4	$68
Ipsen Biopharmaceuticals, Inc	4	$59
Springworks Therapeutics, Inc.	2	$57
Sun Pharmaceutical Industries Inc.	3	$54
Stemline Therapeutics Inc.	2	$52
Servier Pharmaceuticals LLC	2	$46
Sobi, Inc	3	$46
G1 Therapeutics, Inc.	2	$46
GE HealthCare	2	$44
Pharmaessentia USA Corporation	2	$39

How this compares

$5,871,081 in reported general payments places this provider in the 95th percentile of 507 medical oncology providers in Florida.

See all medical oncology providers in Florida →

Medicare billing

Part B allowed, 2024

$7,255,712

Medicare patients

1,171

Services billed

419,600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Sarasota

Manish PatelSarasota$29.7M
Judy WangSarasota$9.8M
Scott LuninSarasota$3M
Anjan PatelSarasota$3M
Zeynep ErogluTampa$30.9M
Jad ChahoudTampa$21.8M
Maen HusseinTavares$18.4M
Patrick HwuTampa$18M
Gail WrightHudson$13.8M
Adil DaudTampa$13.3M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →